Prime Therapeutics Mounjaro Prior Authorization: 2026 Criteria, Checklist & Denial Fix
What Prime’s public forms actually require — and how to fix it when the request bounces back.
By The RX Index Editorial Team — Last verified: . Next review: July 11, 2026. Educational only — not medical advice. Your prescriber and health plan decide what’s medically necessary and covered. The RX Index may earn a commission if you start care through some links, at no cost to you. It never changes our criteria — the insurance steps here are free and unaffiliated.
If you searched “Prime Therapeutics Mounjaro prior authorization,” you’re probably holding one of three things.
A pharmacy rejection. A denial letter. Or a message from your doctor’s office that says “Prime denied it.” Take a breath. A denial is usually not the end — it’s usually a paperwork gap, and paperwork gaps are fixable.
Here’s the bottom line, up front: on the Prime Therapeutics plans we reviewed, the strongest prior authorization for Mounjaro is built around type 2 diabetes — with a documented diagnosis and lab proof — not weight loss. The criteria commonly ask for a type 2 diabetes diagnosis confirmed by a lab test, no other GLP-1 drug at the same time, no DPP-4 medication overlap, no FDA-listed safety conflicts, and a dose that fits Prime’s quantity limits.
Quick orientation — your situation → your strongest next step
| Your situation | The likely issue | Your strongest next step |
|---|---|---|
| You have type 2 diabetes and have old lab results | Good-fit path — if the paperwork is complete | Ask your prescriber to attach your diabetes diagnosis, lab reports, chart notes, dose, and fill history |
| Your A1C is now under 6.5% because the drug is working | Prime may not "see" the proof that you had diabetes | Send the original lab that diagnosed you, plus proof the medicine is helping |
| You want Mounjaro for weight loss only | High denial risk — Mounjaro is approved for diabetes, not weight loss | Ask about Zepbound (a separate tirzepatide brand approved for weight management) if your plan covers it |
| You take Januvia, Janumet, or another DPP-4 pill | Conflict risk — Prime usually won't pay for both | Have your prescriber review your medication list before submitting |
| You already take another GLP-1 (Ozempic, Wegovy, etc.) | Conflict risk — usually only one GLP-1 at a time | Clarify the switch plan so two GLP-1s aren't billed at once |
| You need the 2.5 mg dose long-term | Quantity-limit risk — 2.5 mg is treated as a starter dose | Your prescriber must explain why a labeled maintenance dose won't work |
What we actually verified (and what we couldn’t)
We don’t ask you to take our word for it. Here’s what we read with our own eyes to write this guide, and what’s still on you to check.
Verified from primary sources (June 11, 2026)
- ✓Prime Therapeutics (and its member site, MyPrime) states that some drugs need prior authorization before coverage, and that the physician must submit the request.
- ✓Prime Therapeutics is the pharmacy benefit manager (PBM) for many Blue Cross Blue Shield plans — including BCBS of Illinois, Texas, Oklahoma, New Mexico, and Montana (together called HCSC) — plus other plans and large employers.
- ✓Prime's commercial GLP-1 prior-authorization forms ask the prescriber to confirm a type 2 diabetes diagnosis and to attach chart notes or lab results proving it.
- ✓Prime's GLP-1 criteria commonly require no second GLP-1, no DPP-4 medication at the same time, no FDA-labeled contraindications, and a dose within quantity limits.
- ✓On the current HCSC GLP-1 program summary (effective May 11, 2026), Mounjaro's 2.5 mg strength carries a 180-day supply limit, while every higher strength is limited to 4 pens per 28 days, with a fill limit of one injectable GLP-1 and one strength per 28 days.
- ✓Prime accepts electronic requests through CoverMyMeds and by fax; the pharmacy claim rejects with code "75 — Prior Authorization Required" until it's approved.
- ✓Approvals last up to 12 months on the plans we reviewed, then need renewal.
- ✓Mounjaro (tirzepatide) is FDA-approved to improve blood sugar in adults and children 10 years and older with type 2 diabetes (the pediatric indication was added December 19, 2025). It is not the brand approved for weight loss — that's Zepbound.
- ✓Sesame states its providers can help with prior authorization paperwork for Mounjaro.
- ✓Ro offers a free GLP-1 Insurance Coverage Checker, but Ro's own Mounjaro page says Mounjaro is not currently available through Ro — Ro is useful for the weight-loss brand (Zepbound), not Mounjaro itself.
The proof map — which source backs which fact
| Source we checked | What it proves | Last verified |
|---|---|---|
| MyPrime Prior Authorization page | PA may be required; physician submits; if not approved, you may pay out of pocket | June 11, 2026 |
| HCSC GLP-1 Agonists PA Form | Type 2 diabetes diagnosis, lab confirmation, chart-notes/lab requirement, DPP-4 and GLP-1 overlap questions | June 11, 2026 |
| HCSC GLP-1 Program Summary (eff. May 11, 2026) | Quantity limits, the 2.5 mg 180-day supply limit, one-GLP-1-at-a-time rule | June 11, 2026 |
| Choice GLP-1 PA Form & Criteria | Prescriber-only form, CoverMyMeds, incomplete-form warning, Mounjaro 2.5 mg maintenance question, up to 12-month approval | June 11, 2026 |
| Mounjaro FDA Prescribing Information | FDA-approved indication, dosing, contraindications | June 11, 2026 |
One honest thing before we go further
Prime Therapeutics is not a single insurance plan.
It runs the drug benefits for hundreds of different plans, and each one can set its own formulary, employer exclusions, criteria, and appeal rights. That means no honest article can promise “Prime always covers Mounjaro” or “Prime always denies it.” Anyone who tells you a clean yes or no without asking which plan you have is guessing.
So we’re not going to hand you a fake guarantee. We’re going to hand you something better: the exact evidence checklist Prime’s own forms ask for, so you can check it against your plan and give your doctor’s office a packet that’s hard to deny.
Does Prime Therapeutics cover Mounjaro?
Answer capsule
Prime Therapeutics may cover Mounjaro on your plan — but “covered” does not mean “automatically approved.” Most Prime-administered plans require a prior authorization, and sometimes step therapy or a quantity-limit review, before they’ll pay. If the prior authorization isn’t approved, you can still buy the drug — but you pay full price.
Prime is the gatekeeper, not your insurance plan
Your insurance plan decides the benefits. Prime Therapeutics is the company that runs the pharmacy side of those benefits — building the drug list, reviewing prior-authorization requests, and approving or denying them based on the plan’s rules. So two people can both “have Prime” and still face completely different rules, because their employers or plans chose different options.
“Covered” vs. “approved” — the difference that causes denials
A drug can sit right there on your plan’s formulary (the list of covered drugs) and still require a prior authorization, step therapy, or a quantity-limit check before it’s paid. Seeing Mounjaro on the formulary is good news. It is not the same as approval. When a pharmacy can’t fill your Mounjaro because a prior authorization is needed, the claim rejects with code “75 — Prior Authorization Required.” That’s your signal that your prescriber needs to submit paperwork — not that you’ve been permanently denied.
Your 5-minute Prime plan lookup
Log in to MyPrime (or your insurer’s portal), open your drug list, and find Mounjaro. Here’s how to read what you see:
| What you see next to Mounjaro | What it means | What to ask member services | What to save |
|---|---|---|---|
| PA | Prior authorization required | "Which Mounjaro criteria document applies to my plan?" | Screenshot + date |
| ST | Step therapy may apply | "Which drugs count as required trials first?" | The drug-list page |
| QL | Quantity limit | "What's the limit by strength and day supply?" | The quantity-limit page |
| Non-formulary / Excluded | Benefit-design issue | "Is there an exception or appeal path?" | The exclusion language |
The number to call is on your member ID card. One five-minute call now saves weeks of guessing later.
Where do you find the Prime Therapeutics Mounjaro prior authorization form?
Answer capsule
The right form depends on your member plan, and only your prescriber can submit it. Start at MyPrime or your insurer’s portal, then confirm whether your plan uses the HCSC GLP-1 Agonists form, the Choice GLP-1 form, a CoverMyMeds electronic request, or another plan-specific form before your doctor’s office sends it.
There isn’t one universal form. Prime builds different GLP-1 forms for different plans and employers. The move isn’t to download a random PDF — it’s to confirm which form your plan uses.
Ask the prescriber's office
Most clinics submit through CoverMyMeds (an electronic prior-authorization system), which auto-routes to your plan's correct GLP-1 criteria. This is usually the smoothest path.
Check MyPrime / your insurer portal
Your plan's prior-authorization and step-therapy program list will point to the GLP-1 form your plan uses.
Call the number on your ID card
Ask: "Which Mounjaro GLP-1 prior authorization form does my plan use, and what's the fax or electronic submission path?"
What are the Prime Therapeutics Mounjaro prior authorization criteria in 2026?
Answer capsule
On the Prime/HCSC criteria we reviewed, Mounjaro matched the approval criteria when the request was anchored to type 2 diabetes with lab proof, the patient wasn’t taking a second GLP-1 or a DPP-4 medication, there were no FDA-labeled contraindications, and the dose fit Prime’s quantity limits. Whether step therapy applies — and whether Mounjaro is “preferred” or “non-preferred” — depends on your specific plan’s formulary.
The Prime Mounjaro PA Evidence Matrix
Each thing Prime’s forms ask for — mapped to the exact proof to attach — and what happens if it’s missing.
| What Prime checks | What it means in plain English | What your prescriber should attach | Risk if it’s missing |
|---|---|---|---|
| Right form, right submitter | Only your prescriber can fill out the GLP-1 PA form; it can go through CoverMyMeds or by fax | Your plan's current Prime/MyPrime GLP-1 form, submitted by the doctor's office | High — member-submitted or incomplete forms stall or get returned |
| Type 2 diabetes diagnosis | Mounjaro's approval is tied to type 2 diabetes, not weight loss | ICD-10 diagnosis code (E11.x family) and chart notes confirming type 2 diabetes | Very high — weight-loss-only or off-label requests are far more likely to be denied |
| Lab confirmation | Prime wants evidence of diabetes, not just a checkbox | Copies of the lab(s) with dates: A1C, fasting glucose, OGTT, or random glucose | High — "labs don't show diabetes range" denials are common |
| Step therapy / preferred status | Some plans require trying a preferred drug (often metformin, sometimes a preferred GLP-1) first | Records of what you've already tried, with dates, plus your formulary status | Medium-high — varies by plan; missing trial history triggers denials |
| No DPP-4 combination | Prime usually won't pay for Mounjaro plus a DPP-4 pill (Januvia, Janumet, Tradjenta, Onglyza) | Current medication list, reviewed for DPP-4 overlap | High if a DPP-4 drug is active in your claims |
| No second GLP-1 | Usually only one GLP-1 at a time (no Mounjaro plus Ozempic, Wegovy, Trulicity, etc.) | Medication list showing no overlapping GLP-1, plus a switch plan if changing | High if two GLP-1s are billed at once |
| No FDA-labeled contraindications | Your prescriber must confirm Mounjaro is safe for you | A chart note confirming the safety review | High if the contraindication questions are left blank |
| Dose and quantity within limits | The amount must match Prime's quantity rules | Dose, strength, day supply, and refill history | Medium-high — dose changes and early fills trigger quantity-limit denials |
| 2.5 mg used as maintenance | 2.5 mg is the starter dose; long-term use needs a reason | Written explanation of why a labeled maintenance strength won't work, plus proof it's helping | High if 2.5 mg is requested past the starter phase without explanation |
| Approval length | Approvals run up to 12 months on the plans we reviewed, then renew | A renewal reminder set 60–90 days before expiration | Medium — gaps between approvals interrupt your therapy |
A note on “preferred” vs. “non-preferred”
A preferred drug usually skips step therapy; a non-preferred drug may require you to try a preferred option first. On the current HCSC GLP-1 program summary we read (effective May 11, 2026), Mounjaro’s preferred status is listed as “N.” On another Prime-administered plan it may read differently. Don’t trust a blog that flatly says “Mounjaro is preferred on Prime” — that single label can decide whether step therapy applies to you. Check your own plan’s live drug list.
What diagnosis and lab proof does Prime want for Mounjaro?
Answer capsule
The cleanest Mounjaro approval path on the Prime/HCSC forms we reviewed is type 2 diabetes confirmed by a lab test — and the form requires chart notes or actual lab results, not just a typed-in code. The diagnosis on the form has to match the drug: Mounjaro’s FDA-approved use is type 2 diabetes.
When a request is framed around weight loss alone, it doesn’t match the drug’s approved use — and that mismatch is the number-one reason these requests fall apart. The standard lab tests that confirm type 2 diabetes (the ones Prime’s GLP-1 form points to) are:
Qualifying lab tests for type 2 diabetes diagnosis:
- ✓A1C of 6.5% or higher
- ✓Fasting plasma glucose of 126 mg/dL or higher
- ✓A 2-hour glucose of 200 mg/dL or higher during an oral glucose tolerance test
- ✓A random glucose of 200 mg/dL or higher with symptoms of high blood sugar
Any one of those, documented with a date and attached to the form, is what turns “the patient says they have diabetes” into “here’s the proof.” Ask your prescriber’s office to attach the actual lab report — not just to type the result into a box.
What if your A1C is now under 6.5% because Mounjaro is working?
Answer capsule
This is one of the most frustrating denials, and it’s fixable. When treatment lowers your A1C below the diagnostic line, the plan may not “see” that you ever had diabetes — so your prescriber should send the original diagnostic lab, plus proof the medicine is helping (continuation-of-therapy evidence). The fix is never to exaggerate your current numbers; it’s to document the history.
Think about how unfair this feels. You had high blood sugar. You started Mounjaro. It worked. Now your A1C is great — and that success is being used to deny you. It’s a real, documented friction point, and the fix has three parts.
Send the lab that diagnosed you, not just your latest lab
Ask your prescriber's office for the original A1C, fasting glucose, OGTT, or random-glucose result that first established type 2 diabetes — with its date. A normal current A1C doesn't erase a past diagnosis; the record does the talking.
Add continuation-of-therapy evidence
This is the proof that you're already on Mounjaro and it's working: your pharmacy fill history, your start date, your dose history, a chart note showing clinical benefit, and a note on why stopping would be a problem. Renewals fail when they're submitted like brand-new requests with none of this history.
Don't resubmit the same packet
If the first request got denied for "labs not in range," sending the identical packet again just earns the same denial. Fix the gap first — add the historical lab and the continuation note — then resubmit or appeal.
What should your prescriber actually submit? (the packet that avoids preventable denials)
Answer capsule
The strongest packet answers Prime’s questions before the reviewer has to ask twice: diagnosis, ICD-10 code, lab proof, chart notes, treatment history, current medication list, dose, quantity, day supply, whether it’s new or a renewal, and proof of benefit if you’re continuing. Prime’s GLP-1 form returns incomplete requests for more information — which is exactly the delay you want to avoid.
The Prime Mounjaro PA packet checklist
Hand your doctor’s office this checklist. It mirrors what the form actually asks for.
- ☐Patient name and member ID
- ☐Drug: Mounjaro — with strength and dose
- ☐Day supply and quantity requested
- ☐New therapy or renewal?
- ☐Type 2 diabetes diagnosis with ICD-10 (E11.x) code
- ☐Diagnostic lab report with date (A1C, fasting glucose, OGTT, or random glucose)
- ☐Chart notes confirming the diagnosis
- ☐Current A1C and how you've responded to treatment
- ☐Full current medication list
- ☐Prior diabetes medications tried, with dates (if your plan requires step therapy)
- ☐Pharmacy fill history
- ☐Confirmation there's no DPP-4 drug overlapping
- ☐Confirmation there's no second GLP-1 active
- ☐Confirmation of the FDA-labeled contraindication review
- ☐Quantity-limit reason, if your dose needs an exception
- ☐A 2.5 mg maintenance reason, if you're staying on the starter dose
How it gets submitted
Prime accepts electronic prior-authorization requests through CoverMyMeds, and also takes the form by fax or mail, depending on your plan. A complete packet beats a half-empty one every time — format matters far less than contents.
A simple one-page cover note
If your prescriber is open to it, a short cover note up top makes a reviewer’s job easy:
- “Patient has documented type 2 diabetes.”
- “Diagnosis confirmed by [lab type, date, result].”
- “Mounjaro requested to improve blood sugar control.”
- “Patient is stable and benefiting” (if it’s a renewal).
- “No active DPP-4 or second GLP-1 therapy.”
- “No FDA-labeled contraindication identified.”
- “Requested dose/quantity is within limits” — or — “requires an exception because…”
Need a clinician to evaluate you and help with the paperwork?
Through Sesame’s Success by Sesame program (starting at $59/month annual or $99/month month-to-month; medication not included), a provider can evaluate whether Mounjaro is clinically appropriate and, if so, help with the prior-authorization paperwork.
Sesame is a marketplace — choose a provider with insurance experience. Approval is never guaranteed.
Ask a Sesame provider about Mounjaro PA help → (sponsored affiliate link, opens in a new tab)What are Prime’s Mounjaro quantity limits? (and the 2.5 mg trap)
Answer capsule
On the current HCSC GLP-1 program summary (effective May 11, 2026), Mounjaro’s 2.5 mg starter dose carries a 180-day supply limit, every higher strength is limited to 4 pens per 28 days, and there’s an overall fill limit of one injectable GLP-1 and one strength per 28 days. Asking for 2.5 mg beyond the starter phase — or for a dose or refill outside these limits — needs a specific reason from your prescriber.
Here’s why this catches people. Mounjaro is meant to be started low and stepped up: per the prescribing information, 2.5 mg is the recommended starting dose for the first 4 weeks, then it increases to 5 mg, with further increases of 2.5 mg as needed. Because 2.5 mg is a starter dose, plans treat it differently — that 180-day window is essentially saying “this dose is for getting started, not for staying.”
If you’re doing well on 2.5 mg and want to stay there long-term, your prescriber must answer two questions clearly:
- →Whether you cannot use a labeled maintenance strength
- →Whether you've had clinical benefit on the lower dose
Other quantity tripwires
None of these are dead ends. They just need the dose, day supply, and titration plan spelled out on the form.
Why does Prime deny Mounjaro prior authorizations — and how do you fix each one?
Answer capsule
Most Prime Mounjaro denials fall into a handful of categories — and each maps to a specific missing piece of proof. The big ones: a weight-loss/obesity diagnosis, missing diabetes labs, a current A1C below range with no historical proof, a second GLP-1 or DPP-4 conflict, a dose or quantity issue, or an incomplete form. Almost every one of these is a documentation problem, not a you problem.
| What the denial says | What it usually means | Your next move |
|---|---|---|
| "No type 2 diabetes diagnosis" | The form didn't establish an approved use for Mounjaro | Confirm type 2 diabetes is documented; attach chart notes and labs |
| "A1C not above 6.5" / "labs not in range" | Your current labs don't show diabetes range | Attach the original diagnostic lab plus continuation-of-therapy proof |
| "Not covered for weight loss" | The plan won't pay for Mounjaro for obesity alone | Ask about Zepbound or another weight-loss-labeled option, if covered |
| "Missing information" | Form fields or attachments were incomplete | Ask exactly what's missing, then resubmit complete |
| "Quantity limit exceeded" | Dose, day supply, or refill timing is outside limits | Submit a quantity-limit reason, or align the dose if appropriate |
| "2.5 mg maintenance denied" | The plan treats 2.5 mg as a starter dose | Prescriber documents why a labeled maintenance strength won't work, plus benefit |
| "Duplicate therapy" | Claims show another GLP-1 or a DPP-4 drug | Prescriber reviews the medication list and the switch plan |
| "Not covered under benefit" | The plan design excludes or restricts it | Check the formulary, employer benefit, appeal rights, and alternatives |
What should you do if Prime denies your Mounjaro PA?
Answer capsule
Don’t guess, and don’t just resubmit the same thing. Get the denial reason in writing, find the exact criterion you missed, and have your prescriber resubmit or appeal with the missing proof.
Get the denial reason in writing
- →Which criterion wasn't met — diagnosis, lab proof, step therapy, quantity limit, or a benefit exclusion?
- →Which criteria document was used?
- →What's the appeal deadline?
- →Can the prescriber request a peer-to-peer review (a direct call between your doctor and the plan's reviewer) or a reconsideration?
- →Does the denial allow you to submit more information?
Match the denial to the matrix
Take the reason and find it in the Evidence Matrix above. That tells you the exact proof that was probably missing.
Ask for a targeted resubmission
Use the copy-paste message below — fill in the brackets and send it to your doctor’s office.
Ask about peer-to-peer before a formal appeal
A short call between your prescriber and the plan’s medical reviewer may let your doctor explain the missing documentation directly, before you move into a longer written appeal. Ask whether peer-to-peer or reconsideration is available.
Appeal once the evidence gap is fixed
An appeal is strongest when it directly answers the denial reason. If the internal appeal fails, ask about an external review — an independent review of your case. Your appeal rights and deadlines are plan- and state-specific; confirm them in your denial letter or with member services.
Copy-paste appeal / resubmission message for your prescriber
Fill in the brackets and send it to your doctor’s office:
“Prime denied my Mounjaro prior authorization. The denial reason was [exact wording from the letter], and the appeal deadline is [date]. Before we appeal, can we resubmit with the specific documentation that was missing:
- •Type 2 diabetes diagnosis and ICD-10 code
- •The original diagnostic lab that established my diabetes — [test type], dated [date], result [value]
- •Continuation-of-therapy proof: my fill history, start date, current dose, and a note that the medication is working
- •[If quantity-related]: the reason the requested dose/quantity is medically necessary
Could we also ask whether a peer-to-peer review is available? Thank you.”
That one message turns a vague “they denied me” into a targeted fix the office can act on.
What if you want Mounjaro for weight loss instead of type 2 diabetes?
Answer capsule
Mounjaro is FDA-approved for type 2 diabetes, not weight loss — so if you don’t have diabetes, the cleaner conversation is usually whether your plan covers Zepbound, which shares the same active ingredient (tirzepatide) but is a separate brand approved for weight management. Asking Prime to approve Mounjaro for weight loss alone is a high-risk path.
Mounjaro and Zepbound: same molecule, different doors
Mounjaro and Zepbound both contain tirzepatide — but they are separate brand-name products with separate FDA-approved indications. Mounjaro is the diabetes brand; Zepbound is the weight-management brand. They are not interchangeable on a prior authorization. Don’t let anyone blur the two on your form.
A denial and an exclusion are different problems
If your plan covers weight-loss drugs but denied you, that’s often appealable with better documentation. If your plan excludes weight-loss drugs entirely, no appeal changes the plan’s design. Exclusions are common: in the 2025 KFF Employer Health Benefits Survey, only 19% of large firms (200+ workers) — and 43% of the biggest firms (5,000+ workers) — covered GLP-1s primarily for weight loss. Knowing which one you’re facing tells you whether to fight or pivot.
If insurance is a dead end, you still have real options
If weight loss is your real goal — Ro’s free coverage checker is the right starting point
Note: Ro does not offer Mounjaro. This check is for Zepbound, Wegovy, and other GLP-1 alternatives.
Ro’s free GLP-1 Insurance Coverage Checker contacts your insurer and tells you whether GLP-1s like Zepbound or Wegovy are covered on your plan and roughly what they’d cost. Ro carries Zepbound and Foundayo (an oral GLP-1), with membership starting at $39 for the first month, then as low as $74/month with an annual plan paid upfront (verify current pricing before you commit).
How long does a Prime Mounjaro approval take — and how long does it last?
Answer capsule
Decision time depends on your plan and whether the request is standard or urgent. Once approved, Mounjaro prior authorizations last up to 12 months on the plans we reviewed, then require renewal. Your approval letter states your exact expiration date.
Standard vs. urgent
If waiting would harm your health, your prescriber can request an expedited review, which is faster than a standard one. Ask your doctor's office to flag urgency if it applies.
Complete beats fast
The biggest delay isn't the review clock — it's a returned, incomplete form. The packet checklist above is your best speed tool.
When it’s approved, protect the win
- ✓Set a renewal reminder 60–90 days before your approval expires.
- ✓Save your approval letter, your fill history, your current A1C, your current dose, and any side-effect notes your prescriber may want for the renewal.
- ✓Don't wait until you're out of medication to start the renewal — a gap can interrupt your therapy.
Should you use a telehealth provider to help with Mounjaro? (and when not to)
Answer capsule
For Mounjaro specifically, Sesame is the cleaner fit — Sesame states its providers help with prior-authorization paperwork. Ro is better for the weight-loss brand or a coverage check, since Ro doesn’t carry Mounjaro. No telehealth visit can override your plan’s criteria or guarantee approval.
| Path | Offers Mounjaro? | Helps with the PA? | Verified price | Best fit | The limitation |
|---|---|---|---|---|---|
| Your own prescriber | Yes, if prescribed | Yes, if the office handles it | Plan-specific | You already have diabetes records on file | The office may be slow or unfamiliar with PA |
| Sesame (Success by Sesame) | Provider may prescribe if appropriate | Says its providers can assist with PA paperwork | $59/mo annual, or $99/mo month-to-month (medication not included) | Mounjaro-specific online help when you lack a prescriber | Marketplace model — PA persistence depends on the provider you pick; approval not guaranteed |
| Ro | No — not available through Ro | Free coverage checker for GLP-1 alternatives | $39 first month, then $149/mo (or $74/mo annual) | Zepbound, Wegovy, or Ozempic alternatives + a coverage report | Not a Mounjaro path |
If your own doctor already has your records — start there
Your primary-care doctor or endocrinologist is often your best bet, because the proof that wins a Mounjaro PA — your diagnosis-date labs, your diabetes history, your fill record — is usually already in their files. Switching providers to chase an approval can mean leaving that proof behind.
If you need a clinician and paperwork help — consider Sesame
Through Success by Sesame (starting at $59/month with an annual plan or $99/month month-to-month; the medication isn’t included), a provider can evaluate whether Mounjaro is clinically appropriate and, if so, help with the prior-authorization paperwork. One honest note: Sesame is a marketplace where you choose your provider — choose one with insurance experience, and don’t expect a guarantee, because not every plan covers Mounjaro even with a PA.
Ask a Sesame provider about Mounjaro PA help → (sponsored affiliate link, opens in a new tab)A provider can evaluate whether Mounjaro is right for you and assist with the paperwork if prescribed. Approval is never guaranteed.
When not to use telehealth
Don’t switch providers just to force a PA your chart doesn’t support, and don’t move away from the doctor who holds your key records if those records are what your approval depends on.
How we built this guide (and why you can trust it)
This page was assembled from public Prime Therapeutics and MyPrime prior-authorization pages, Prime’s GLP-1 prior-authorization forms and the current HCSC GLP-1 program summary, Eli Lilly’s Mounjaro prescribing information, and current provider pages for Sesame and Ro. We translated dense insurer documents into a checklist — we did not invent criteria.
Our source priority, in order:
- 1.Official Prime/MyPrime and health-plan documents
- 2.Mounjaro's FDA-approved prescribing information
- 3.Provider pages, used only for honest next-step routing
- 4.Patient discussions, used only to understand real friction — never as a coverage rule
We’re The RX Index, a pricing intelligence and comparison resource for GLP-1 telehealth providers. We make money when some readers start treatment through links on our site, at no cost to you. That never changes our criteria — we’d publish this exact guide with zero links, because the insurance-navigation steps here are free and unaffiliated. If a provider isn’t the right fit for you, we say so (we just did, twice).
Update log. Last verified . Next provider-pricing check: July 11, 2026. Full quarterly re-verification: September 11, 2026. Immediate update triggers: a Prime/HCSC formulary change, an FDA label change for Mounjaro/tirzepatide, or a Sesame/Ro pricing change.
Prime Therapeutics Mounjaro prior authorization: FAQ
- Does Prime Therapeutics require prior authorization for Mounjaro?
- Many Prime-administered plans require a prior authorization for Mounjaro, but the exact requirement depends on your plan and formulary. Prime states that some drugs need prior authorization before coverage and that your physician must submit the request.
- Does Prime Therapeutics approve Mounjaro for weight loss?
- Usually not. The Prime criteria we reviewed are built around type 2 diabetes, and Mounjaro's FDA-approved use is type 2 diabetes — not weight loss. For weight loss, the labeled option is Zepbound, which shares the same active ingredient (tirzepatide) but is a separate brand approved for weight management, if your plan covers it.
- What A1C does Prime require for Mounjaro?
- Prime's GLP-1 form asks for proof of type 2 diabetes confirmed by a standard lab test. An A1C of 6.5% or higher is one qualifying test; a fasting glucose of 126 mg/dL or higher, a 2-hour OGTT of 200 mg/dL or higher, or a random glucose of 200 mg/dL or higher with symptoms also qualify. Confirm your plan's exact criteria before submitting.
- Can I be denied if my A1C is now under 6.5% because the drug is working?
- Yes — it's a common documentation snag. Your prescriber should attach the original diagnostic lab that established your diabetes, plus continuation-of-therapy proof showing the medicine is helping, rather than relying on your current (now-normal) number.
- Where do I find the Prime Therapeutics Mounjaro prior authorization form?
- The form depends on your plan, and only your prescriber can submit it. Start at MyPrime or your insurer portal, then confirm whether your plan uses the HCSC GLP-1 form, the Choice GLP-1 form, or a CoverMyMeds electronic request before your doctor's office sends it.
- What should my doctor submit for a Mounjaro PA?
- Diagnosis with ICD-10 code, lab proof with dates, chart notes, treatment history, current medication list, dose, day supply, whether it's new or a renewal, confirmation of no second GLP-1 or DPP-4 overlap, a contraindication review, and a quantity-limit reason if needed.
- Does Mounjaro 2.5 mg need a quantity-limit exception?
- It can. On the HCSC summary we reviewed, 2.5 mg carries a 180-day supply limit because it's the starter dose. Prime's form asks whether you can't use a labeled maintenance strength and whether you've benefited from the lower dose — your prescriber must answer both to stay on 2.5 mg long-term.
- How long does a Prime Mounjaro approval last?
- Up to 12 months on the plans we reviewed, then it must be renewed. Your approval letter has your exact expiration date — start the renewal 60 to 90 days early.
- Can Ro help with Mounjaro prior authorization?
- Ro offers a free GLP-1 coverage checker, but Ro's own Mounjaro page states Mounjaro is not currently available through Ro. Use Ro to check GLP-1 coverage generally and for the weight-loss brand Zepbound, not as your Mounjaro PA path.
- Can Sesame help with Mounjaro prior authorization?
- Sesame states its providers can assist with Mounjaro prior-authorization paperwork through Success by Sesame (starting at $59/month with an annual plan or $99/month month-to-month; medication not included). That helps with the paperwork — it does not guarantee your plan approves coverage.
- What if my Prime Mounjaro PA is denied?
- Get the exact denial reason and the appeal deadline in writing, match the reason to the missing proof, then have your prescriber resubmit or appeal with that proof. Ask whether peer-to-peer or reconsideration is available before a formal appeal. Don't resubmit the same incomplete packet.
- Is Zepbound better than Mounjaro for weight-loss coverage?
- If your goal is weight loss and you don't have type 2 diabetes, Zepbound is usually the cleaner labeled path — if your plan covers weight-loss drugs. Your plan can still require a prior authorization and may exclude weight-loss drugs entirely.
Still not sure which GLP-1 program is right for you?
You’ve got the criteria, the packet checklist, the denial fixes, and the alternatives. If you’d rather get a personalized next step than piece it together yourself, the quiz turns all of it into a personalized action plan in about a minute.
Take the free 60-second GLP-1 matching quiz →Related guides
Sources
- 1.Prime Therapeutics (MyPrime) — Prior Authorization: https://www.myprime.com/en/forms/coverage-determination/prior-authorization.html
- 2.Prime Therapeutics — Provider Prior Authorization (reject code 75, CoverMyMeds, fax): https://web.primetherapeutics.com/provider/#!/priorauth
- 3.Prime Therapeutics — HCSC GLP-1 Agonists Program Summary (eff. May 11, 2026; quantity limits, 2.5 mg 180-day limit): https://www.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/HCSC/Program_Summaries/HCSC_GLP-1_Agonists_ProgSum.pdf
- 4.Prime Therapeutics — HCSC GLP-1 Agonists PA Form (type 2 diabetes + lab confirmation): https://www.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/HCSC/Fax_Forms/HCSC_GLP-1_Agonists_PA.pdf
- 5.Prime Therapeutics — Choice GLP-1 PA Form (prescriber-only; 2.5 mg maintenance; up to 12-month approval): https://web.primetherapeutics.com/provider/external/commercial/common/doc/en-us/Choice_GLP1_PA_Form.pdf
- 6.Mounjaro (tirzepatide) FDA Prescribing Information (type 2 diabetes indication; dosing; contraindications): https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf
- 7.Blue Cross Blue Shield of Texas — Prior Authorization & Step Therapy: https://www.bcbstx.com/provider/pharmacy/pharmacy-program/pa-step-therapy
- 8.Blue Cross Blue Shield of Oklahoma — GLP-1 New to Therapy (30-day initial fills): https://www.bcbsok.com/provider/education/education-reference/news-updates/2024/glp-1-new-to-therapy-optional-benefit-program-available-for-select-commercial-members0
- 9.KFF — 2025 Employer Health Benefits Survey (GLP-1 weight-loss coverage by firm size): https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
- 10.Eli Lilly — Zepbound Savings & Self-Pay Pricing: https://zepbound.lilly.com/savings
- 11.Sesame — Mounjaro (providers assist with PA; Success by Sesame pricing): https://sesamecare.com/medication/mounjaro
- 12.Ro — GLP-1 Insurance Coverage Checker: https://ro.co/weight-loss/glp1-insurance-checker/
- 13.Ro — Mounjaro page (Mounjaro not currently available through Ro): https://ro.co/weight-loss/mounjaro/
Mounjaro, Zepbound, Ozempic, Wegovy, Rybelsus, Trulicity, and Foundayo are trademarks of their respective owners. This page is independent and is not affiliated with Prime Therapeutics, Eli Lilly, or any health plan.